Financial Report: Merck

Merck

1Q Revenues: $9.3 billion (+3%)

1Q Earnings: $1.1 billion (+18%)

Comments: Pharmaceutical sales were $8.1 billion in the quarter, down 2%. JANUVIA / JANUMET sales were $1.4 billion, up 4%. ZETIA / VYTORIN sales were $889 million, up 4%. KEYTRUDA sales were $249 million in the quarter, which continues to launch with new indications in new markets. CUBICIN sales were up 57% to $292 million. 1Q15 reflects approximately two months of sales following the acquisition of Cubist Pharmaceuticals, Inc. in Jan. 2015. In June 2016, the company will lose U.S. patent protection for CUBICIN. GARDASIL / GARDASIL 9 sales were $378 million, up 7%. REMICADE sales were down 26% to $349 million impacted by biosimilar competition in Europe. ISENTRESS sales were $340 million, down 8%. NASONEX sales were down 19% to $229 million. A generic version became available in the U.S. in March 2016 and sales are expected to further decline.